INTRODUCTION: Ribociclib is an orally bioavailable cyclin-dependent kinase 4/6 inhibitor. In combination with aromatase inhibitor letrozole, it has approval for treatment of hormone receptor positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer. First-line therapy with ribociclib + letrozole significantly improves progression-free survival compared to placebo + letrozole in patients with HR+/HER2- advanced breast cancer. In patients with de novo advanced or metastatic breast cancer, ribociclib was able to provide substantial clinical benefit according to data from the MONALEESA-2 study. CASE PRESENTATION: Here, we report the complete clinical response in a postmenopausal patient with de novo, locally advanced, pulmonary metastatic breast cancer treated with ribociclib + letrozole. Our patient presented an ulcerated breast-consuming tumor with multiple pulmonary metastases. HR+/HER2- breast cancer was confirmed by tumor biopsy. Ki67 expression was 90%. After three months of initial treatment, the tumor-associated ulcerations disappeared, and no measurable pulmonary disease was detectable on CT scan. Treatment was well tolerated, and after dosage reduction due to neutropenia, no further side effects have been documented. At present, complete clinical response remains after 15 months of ongoing treatment. CONCLUSION: This case report documents an exceptional tumor response of a fast growing, locally advanced, pulmonary metastatic HR+/HER2- de novo breast cancer treated by ribociclib/letrozole combination therapy. Treatment success was long lasting with few side effects. The patient was very satisfied with the treatment and had no specific restrictions in her daily life.
INTRODUCTION: Ribociclib is an orally bioavailable cyclin-dependent kinase 4/6 inhibitor. In combination with aromatase inhibitor letrozole, it has approval for treatment of hormone receptor positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer. First-line therapy with ribociclib + letrozole significantly improves progression-free survival compared to placebo + letrozole in patients with HR+/HER2- advanced breast cancer. In patients with de novo advanced or metastatic breast cancer, ribociclib was able to provide substantial clinical benefit according to data from the MONALEESA-2 study. CASE PRESENTATION: Here, we report the complete clinical response in a postmenopausal patient with de novo, locally advanced, pulmonary metastatic breast cancer treated with ribociclib + letrozole. Our patient presented an ulcerated breast-consuming tumor with multiple pulmonary metastases. HR+/HER2- breast cancer was confirmed by tumor biopsy. Ki67 expression was 90%. After three months of initial treatment, the tumor-associated ulcerations disappeared, and no measurable pulmonary disease was detectable on CT scan. Treatment was well tolerated, and after dosage reduction due to neutropenia, no further side effects have been documented. At present, complete clinical response remains after 15 months of ongoing treatment. CONCLUSION: This case report documents an exceptional tumor response of a fast growing, locally advanced, pulmonary metastatic HR+/HER2- de novo breast cancer treated by ribociclib/letrozole combination therapy. Treatment success was long lasting with few side effects. The patient was very satisfied with the treatment and had no specific restrictions in her daily life.
Authors: Cynthia X Ma; Feng Gao; Jingqin Luo; Donald W Northfelt; Matthew Goetz; Andres Forero; Jeremy Hoog; Michael Naughton; Foluso Ademuyiwa; Rama Suresh; Karen S Anderson; Julie Margenthaler; Rebecca Aft; Timothy Hobday; Timothy Moynihan; William Gillanders; Amy Cyr; Timothy J Eberlein; Tina Hieken; Helen Krontiras; Zhanfang Guo; Michelle V Lee; Nicholas C Spies; Zachary L Skidmore; Obi L Griffith; Malachi Griffith; Shana Thomas; Caroline Bumb; Kiran Vij; Cynthia Huang Bartlett; Maria Koehler; Hussam Al-Kateb; Souzan Sanati; Matthew J Ellis Journal: Clin Cancer Res Date: 2017-03-07 Impact factor: 12.531
Authors: Stephen Johnston; Shannon Puhalla; Duncan Wheatley; Alistair Ring; Peter Barry; Chris Holcombe; Jean Francois Boileau; Louise Provencher; André Robidoux; Mothaffar Rimawi; Stuart A McIntosh; Ibrahim Shalaby; Robert C Stein; Michael Thirlwell; David Dolling; James Morden; Claire Snowdon; Sophie Perry; Chester Cornman; Leona M Batten; Lisa K Jeffs; Andrew Dodson; Vera Martins; Arjun Modi; C Kent Osborne; Katherine L Pogue-Geile; Maggie Chon U Cheang; Norman Wolmark; Thomas B Julian; Kate Fisher; Mairead MacKenzie; Maggie Wilcox; Cynthia Huang Bartlett; Maria Koehler; Mitch Dowsett; Judith M Bliss; Samuel A Jacobs Journal: J Clin Oncol Date: 2018-12-06 Impact factor: 44.544
Authors: P Cottu; V D'Hondt; S Dureau; F Lerebours; I Desmoulins; P-E Heudel; F P Duhoux; C Levy; M-A Mouret-Reynier; F Dalenc; J-S Frenel; C Jouannaud; L Venat-Bouvet; S Nguyen; J-M Ferrero; J-L Canon; J Grenier; C Callens; D Gentien; J Lemonnier; A Vincent-Salomon; S Delaloge Journal: Ann Oncol Date: 2018-12-01 Impact factor: 32.976
Authors: G N Hortobagyi; S M Stemmer; H A Burris; Y S Yap; G S Sonke; S Paluch-Shimon; M Campone; K Petrakova; K L Blackwell; E P Winer; W Janni; S Verma; P Conte; C L Arteaga; D A Cameron; S Mondal; F Su; M Miller; M Elmeliegy; C Germa; J O'Shaughnessy Journal: Ann Oncol Date: 2018-07-01 Impact factor: 32.976
Authors: Joyce O'Shaughnessy; Katarina Petrakova; Gabe S Sonke; Pierfranco Conte; Carlos L Arteaga; David A Cameron; Lowell L Hart; Cristian Villanueva; Erik Jakobsen; Joseph T Beck; Deborah Lindquist; Farida Souami; Shoubhik Mondal; Caroline Germa; Gabriel N Hortobagyi Journal: Breast Cancer Res Treat Date: 2017-11-21 Impact factor: 4.872
Authors: Hui Miao; Mikael Hartman; Nirmala Bhoo-Pathy; Soo-Chin Lee; Nur Aishah Taib; Ern-Yu Tan; Patrick Chan; Karel G M Moons; Hoong-Seam Wong; Jeremy Goh; Siti Mastura Rahim; Cheng-Har Yip; Helena M Verkooijen Journal: PLoS One Date: 2014-04-02 Impact factor: 3.240